Table 2.

Associations of mineral metabolite (FGF23, 1,25[OH]2D, and 25[OH]D concentrations) × genotype with annualized percentage change in height-adjusted total kidney volume in HALT-PKD Study A

Associationβ-Estimate (95% CI)
FGF23 × Genotype1,25(OH)2D × Genotype25(OH)D × Genotype
UnadjustedAdjustedUnadjustedAdjustedUnadjustedAdjusted
PKD1 truncating × mineral metaboliteReferenceReferenceReferenceReferenceReferenceReference
PKD1 nontruncating × mineral metabolite−1.52 (−3.89 to 0.85)−0.72 (−2.93 to 1.49)0.03 (−0.06 to 0.12)0.02 (−0.07 to 0.10)0.05 (−0.04 to 0.14)0.06 (−0.03 to 0.14)
PKD2 × mineral metabolite−1.57 (−4.39 to 1.26)−1.20 (−3.82 to 1.43)−0.01 (−0.11 to 0.09)0.02 (−0.07 to 0.12)0.15 (0.03 to 0.28)0.16 (0.04 to 0.28)
NMD × mineral metabolite−0.95 (−4.55 to 2.65)−0.74 (−4.08 to 2.61)0.02 (−0.11 to 0.14)0.01 (−0.10 to 0.13)0.09 (−0.10 to 0.28)0.09 (−0.09 to 0.27)
  • Adjusted model is adjusted for age, sex, body mass index, systolic BP, randomization group, calcium, phosphorus, baseline eGFR, baseline height-adjusted total kidney volume, and urinary albumin excretion. FGF23, fibroblast growth factor 23; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; HALT-PKD, Halt Progression of Polycystic Kidney Disease; NMD, no mutation detected.